natgillin/translations-raw huggingface dataset:
A hair brush (10) as set forth in claim 2 in which the uniform amount is approximately 0.007 metres. 
Četka za kosu (10) u skladu s patentnim zahtjevom 2, naznačena time što je ujednačena vrijednost otprilike 0,007 metara.
A hair brush (10) as set forth in claim 2 in which the longer bristles (12a) and shorter bristles (12b) are preferably approximately 0.014 and 0.007 metres long, respectively. 
Četka za kosu (10) u skladu s patentnim zahtjevom 2, naznačena time što su dulje čekinje (12a) odnosno kraće čekinje (12b) po mogućnosti duge otprilike 0,014 odnosno 0,007 metara.
A hair brush (10) as set forth in claim 1 or claim 2 in which a short bristle (12b) is at the centre of each group of four longer bristles (12a), except at the peripheral edge of the bristles. 
Četka za kosu (10) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što je u središtu svake skupine od četiri dulje čekinje (12a) kratka čekinja (12b), osim na vanjskom rubu čekinja.
A hair brush (10) as set forth in claim 1 or claim 2 in which the free ends of the longer bristles define a first surface (Y), and said first surface is curved, the better to conform to the shape of a human head. 
Četka za kosu (10) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što slobodni krajevi duljih čekinja definiraju prvu površinu (Y), gdje je navedena prva površina zaobljena, kako bi bolje odgovarala obliku ljudske glave.
A hair brush (10) as set forth in claim 6 in which said first surface (Y) is concave. 
Četka za kosu (10) u skladu s patentnim zahtjevom 6, naznačena time što je navedena prva površina (Y) konkavna.
A hair brush (10) as set forth in claim 1 or claim 2 in which the body (10b) is shaped, on the area where said bristles (12a, 12b) reside, to be curved. 
Četka za kosu (10) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što je tijelo (10b) takvog oblika, na površini na kojoj se nalaze navedene čekinje (12a, 12b), da je zaobljeno.
A hair brush (10) as set forth in claim 1 or claim 2 in which the body is concave (10b), so that it corresponds to the shape of said first surface (Y) defined by said free ends of said longer bristles (12a). 
Četka za kosu (10) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što je tijelo konkavno (10b), tako da odgovara obliku navedene prve površine (Y), koju definiraju navedeni slobodni krajevi navedenih duljih čekinja (12a).
A hair brush (10) as set forth in claim 6 in which the free ends of the shorter bristles (12b) define a second surface (X) spaced from said first surface (Y) by a uniform distance. 
Četka za kosu (10) u skladu s patentnim zahtjevom 6, naznačena time što slobodni krajevi kraćih čekinja (12b) definiraju drugu površinu (X), odmaknutu od navedene prve površine (Y) ujednačenim razmakom.
A process wherein a compound of formula II wherein R' and R" independently represent one, two or three hydrogen, halogen, C1-6-alkyl or C2-6-alkylene and L represents a leaving group is reacted with an optionally substituted N-benzyl-4-piperidone wherein R"' represents hydrogen or -O-C1-6-alkyl, to obtain a compound of formula III 
Postupak gdje spoj formule II [image] pri čemu R’ i R" nezavisno predstavljaju jedan, dva ili tri vodika, halogen, C1-6-alkil ili C2-6-alkilen i L predstavlja odlazeću skupinu, reagira s N-benzil-4-piperidonom koji može biti po izboru supstituiran [image] gdje R"’ predstavlja vodik ili -O-C1-6-alkil, radi dobivanja spoja formule III [image]
The process according to any of claims 2-4, wherein the metallation agent is n-butyl lithium. 
Postupak prema bilo kojem od zahtjeva 2-4, gdje sredstvo za dodavanje atoma metala n-butil litij.
A process for the manufacture of compound I and acid addition salts thereof, wherein R' and R" independently represent one, two or three hydrogen, halogen, C1-6-alkyl or C2-6-alkylene, said process comprising the steps of reacting a compound of formula II wherein L represents a leaving group, with an optionally substituted N -benzyl-4-piperidone wherein R"' represents hydrogen or O-C1-6-alkyl, to obtain a compound of formula III 
Postupak proizvodnje spoja I [image] i njegovih kiselih adicijskih soli, gdje R’ i R" nezavisno predstavljaju jedan, dva ili tri vodika, halogen, C1-6-alkil ili C2-6-alkilen, a postupak obuhvaća korak reakcije spoja formule II [image] gdje L predstavlja odlazeću skupinu, s N-benzil-4-piperidonom koji može biti po izboru supstituiran [image] gdje R"’ predstavlja vodik ili O-C1-6-alkil, radi dobivanja spoja formule III [image]
The process according to any of claims 7-9, wherein the metallation agent is n-butyl lithium 
Postupak prema bilo kojem od zahtjeva 7-9, gdje je sredstvo za dodavanje atoma metala n-butil litij
The process according to any of claims 6-11, wherein said salt is the hydrobromic acid addition salt. 
Postupak prema bilo kojem od zahtjeva 6-11, gdje je navedena sol adicijska sol bromovodične kiseline.
The process according to claim 6, wherein compound I is or acid addition salts thereof said process comprising the steps of reacting with n-butyl lithium at a temperature below 0 °C followed by reaction with N-benzyl-4-piperidone at a temperature between around 5°C and around -25 °C and HCl to obtain a compound of the formula which compound is further reacted with ethyl chloroformate to obtain a compound of the formula which compound is further reacted with Et3SiH and trifluoro acetic acid followed by reaction with an acid to remove the N-piperidine protecting group and optionally to obtain a desired acid addition salt. 
Postupak prema zahtjevu 6, gdje je spoj I [image] ili njegove kisele adicijske soli taj postupak obuhvaća korake reakcije [image] s n-butil litijem pri temperaturi ispod 0°C, nakon čega slijedi reakcija s N-benzil-4-piperidonom pri temperaturi između oko 5°C i oko -25°C i HCl radi dobivanja spoja formule [image] a taj spoj dalje reagira s etil kloroformatom radi dobivanja spoja formule [image] a taj spoj dalje reagira s Et3SiH i trifluor octenom kiselinom, nakon čega slijedi reakcija s kiselinom da se ukloni N-piperidin zaštitna skupina i po izboru da se dobije željena kisela adicijska sol.
The process according to any of claims 13-14, wherein said salt is the hydrobromic acid addition salt and wherein the N-protecting group is removed by reaction with hydrobromic acid in acetic acid. 
Postupak prema bilo kojem od zahtjeva 13-14, gdje je navedena sol adicijska sol bromovodične kiseline i gdje se N-zaštitna skupina uklanja reakcijom s bromovodičnom kiselinom u octenoj kiselini.
A process for the manufacture of a compound of the formula or acid addition salts thereof, the process comprising the steps of reacting a compound of the formula with ethyl chloroformate to obtain a compound of the formula which compound is further reacted with Et3SiH and trifluoro acetic acid followed by reaction with an acid to remove the N-piperidine protecting group and optionally to obtain a desired acid addition salt. 
Postupak proizvodnje spoja formule [image] ili njegovih kiselih adicijskih soli, postupak obuhvaća korake reakcije spoja formule [image] s etil kloroformatom radi dobivanja spoja formule [image] a taj spoj dalje reagira s Et3SiH i trifluor octenom kiselinom, nakon čega slijedi reakcija s kiselinom da se ukloni N-piperidin zaštitna skupina i po izboru da se dobije željena kisela adicijska sol.
The process according to claim 16, wherein said salt is the hydrobromic acid addition salt and wherein the N-protecting group is removed by reaction with hydrobromic acid in acetic acid. 
Postupak prema zahtjevu 16, gdje je navedena sol adicijska sol bromovodične kiseline i gdje se N-zaštitna skupina uklanja reakcijom s bromovodičnom kiselinom u octenoj kiselini.
The compound according to claim 2, which compound has an XRDP as shown in any of figures 1-17. 
Spoj prema zahtjevu 2, taj spoj ima obrazac rendgenske difrakcije (XRDP) kako je prikazano na bilo kojoj od slika 1-17.
The compound according to claim 1 which is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine hydrobromide salt in a crystalline form. 
Spoj prema zahtjevu 1 koji je bromovodična sol 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina u kristalnom obliku.
The compound according to claim 4, which compound has an XRDP as shown in figure 3. 
Spoj prema zahtjevu 4, taj spoj ima XRDP kako je prikazano na slici 3.
The composition according to claim 8, said composition being a tablet prepared by wet granulation and comprising anhydrous calcium hydrogen phosphate, corn starch, PVP-VA copolymer, microcrystalline cellulose, sodium starch glycolate, talc and magnesium stearate. 
Oblik prema zahtjevu 8, taj je oblik tableta pripremljena mokrom granulacijom i sadrži bezvodni kalcijev hidrogenfosfat, kukuruzni škrob, PVP-VA kopolimer, mikrokristaliničnu celulozu, natrij škrob glikolat, talk i magnezijev stearat.
A compound according to any of claims 1-6 for use in the treatment of a disease selected from affective disorders, depression, major depressive disorder, postnatal depression, depression associated with bipolar disorder, Alzheimer's disease, psychosis, cancer, age or Parkinson's disease, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, panic attacks, phobia, social phobia, agoraphobia, stress urinary incontinence, emesis, IBS, eating disorders, chronic pain, partial responders, treatment resistant depression, Alzheimer's disease, cognitive impairment, ADHD, melancholia, PTSD, hot flushes, sleep apnea, alcohol, nicotine or carbohydrate craving, substance abuse and alcohol or drug abuse. 
Spoj prema bilo kojem od zahtjeva 1-6 za uporabu u liječenju bolesti izabrane između afektivnih poremećaja, depresije, velikog depresivnog poremećaja, post-porođajne depresije, depresije povezane s bipolarnim poremećajem, Alzheimerove bolesti, psihoze, raka, starosti ili Parkinsonove bolesti, anksioznosti, općeg anksioznog poremećaja, socijalnog anksioznog poremećaja, opsesivno kompulzivnog poremećaja, paničnog poremećaja, napada panike, fobije, socijalne fobije, agorafobije, stres urinarne inkontinencije, povraćanja, sindroma iritabilnog crijeva (IBS), poremećaja hranjenja, kronične boli, kod bolesnika koji djelomično odgovaraju na liječenje, depresije otporne na liječenje, Alzheimerove bolesti, kognitivnog poremećaja, poremećaja deficita pažnje i hiperaktivnosti (ADHD), melankolije, post-traumatskog stresnog poremećaja (PTSD), valova vrućine, poremećaja disanja u snu, želje za alkoholom, nikotinom ili ugljikohidratima, ovisnosti o supstancama te ovisnosti o alkoholu ili drogama.
A process for the preparation of the compound of claim 1 the process comprising reacting compound II wherein R' represent hydrogen or a mono-valent metal ion, with a compound of formula III wherein X1 and X2 independently represent halogen, and a compound of formula IV wherein R represent hydrogen or a protecting group, in the presence of a solvent, a base and a palladium catalyst consisting of a palladium source and a phosphine ligand at a temperature between 60°C and 130°C. 
Postupak pripreme spoja prema zahtjevu 1 [image] postupak obuhvaća reakciju spoja II [image] gdje R’ predstavlja vodik ili monovalentni ion metala, sa spojem formule III [image] gdje X1 i X2 nezavisno predstavljaju halogen, i spojem formule IV [image] gdje R predstavlja vodik ili zaštitnu skupinu, u prisutnosti otapala, baze i paladijskog katalizatora koji se sastoji od izvora paladija i liganda fosfina, na temperaturi između i .
The process according to claim 12, wherein compound II and compound III are reacted in a first reaction, and wherein the reaction product for said first reaction is optionally isolated and purified, followed by a subsequent reaction with the compound IV. 
Postupak prema zahtjevu 12, gdje spoj II i spoj III reagiraju u prvoj reakciji, i gdje se produkt [image] te prve reakcije po izboru izolira i pročišćava, nakon čega slijedi reakcija sa spojem IV.
The process according to claim 12, wherein compound II, compound III and compound IV are mixed together at the start of the process. 
Postupak prema zahtjevu 12, gdje se spoj II, spoj III i spoj IV miješaju zajedno na početku postupka.
The process according to claim 23, wherein said resulting mixture is heated to reflux for 4-6 hours, and which process is followed by a subsequent step in which the obtained product is further reacted with aqueous HBr to obtain the corresponding hydrobromic acid addition salt. 
Postupak prema zahtjevu 23, pri čemu se dobivena smjesa zagrijava do refluksa 4-6 sati, i nakon čega slijedi sljedeći korak gdje dobiveni produkt dalje reagira s vodenim HBr da se dobije odgovarajuća adicijska sol bromovodične kiseline.
Ar2 is selected from the group consisting of phenylene, fluorophenylene, methoxyphenylene and pyridinediyl; 
Ar2 se bira iz skupine koju čine fenilen, fluorfenilen, metoksifenilen i piridindiil;
Z is selected from the group consisting of (CH2)nCOOH, n is 0; and q is 0; and pharmaceutically acceptable salts thereof. 
Z se bira iz skupine koju čine (CH2)nCOOH, [image] n je 0; i q je 0; i njegove farmaceutski prihvatljive soli.
A compound according to Claim 1 wherein Ar2 is attached at the 1-3 position. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što Ar2 je vezan na položajima 1-3.
for a compound of formula I where Z is COOH, hydrolysis of a compound of formula II where R10 is cyano; and 
za spoj formule I, gdje je Z COOH, [image] hidrolize spoja formule II, gdje je R10 cijano; i [image]
and R10 is CN or COOR14 in which R14 is selected from the group consisting of C1-C5 alkyl, phenyl and benzyl. 
je CN ili COOR14, gdje se R14 bira iz skupine koju čine C1-C5 alkil, fenil i benzil.
A process for preparing 3- {[4-(4-acetyl-3-hydroxy-2-propyl-phenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid or a pharmaceutically acceptable salt thereof, comprising 
Postupak dobivanja 3-{[4-(4-acetil-3-hidroksi-2-propilfenoksimetil)fenil]-(S)-hidroksimetil}benzojeve kiseline, ili njezine farmaceutski prihvatljive soli, naznačen time što se sastoji u
The use according to claim 1, where dose a is within the range of from 10 to 90 wt.-% of dose b. 
Tapentadol prema patentnom zahtjevu 1 ili 2, naznačen time da je doza a unutar raspona od 10 do 90 % po težini doze b.
The use according to claim 3, where dose a is within the range of from 10 to 65 wt.-% of dose c and where dose b is within the range of from 35 to 90 wt.-% of dose c. 
Tapentadol prema patentnom zahtjevu 4, naznačen time da je doza a unutar raspona od 10 do 65 % po težini doze c i da je doza b unutar raspona od 35 do 90 % po težini doze c.
Wind power turbine as claimed in claim 10 and 13, wherein the annular grooves (45, 46) are formed along respective conical surfaces (31, 37) of the stator (12). 
Vjetroturbina u skladu s patentnim zahtjevom 10 i 13, naznačena time, da su prstenasti žljebovi (45, 46) izrađeni duž dotičnih konusnih površina (31, 37) statora (12).
Pharmaceutical composition according to claim 11 or 12 for the treatment of affective disorders. 
Farmaceutski pripravak prema zahtjevu 11 ili 12 naznačen time da je za uporabu kod liječenja afektivnih poremećaja.
Pharmaceutical composition according to claim 13, wherein the affective disorder is selected from depression, anxiety, bipolar disorder and schizophrenia. 
Farmaceutski pripravak naznačen time da je za uporabu kod liječenja afektivnih poremećaja prema zahtjevu 13, pri čemu afektivni poremećaj je odabran od depresije, tjeskobe, bipolarnog poremećaja i shizofrenije.
Pharmaceutical composition according to claim 11 or 12, for the treatment of neurodegenerative diseases and disorders, diseases and disorders which are mediated by or result in neuroinflammation and centrally-mediated neuropsychiatric diseases and disorders. 
Farmaceutski pripravak prema zahtjevu 11 ili 12, naznačen time da je za uporabu kod liječenja neurodegenerativnih bolesti i poremećaja, bolesti i poremećaja koji su posredovani sa ili rezultiraju sa neurološkim upalama i središnje posredovanim neuropsihijatrijskim bolestima i poremećajima.
Pharmaceutical composition according to claim 11 or 12, for the treatment of neuropathic pain. 
Farmaceutski pripravak prema zahtjevu 11 ili 12, naznačen time da je za uporabu kod liječenja neuropatske boli.
The single pipe collector according to claim 1, characterised in that the indentations and/or elevations (16) are evenly spread around the inner circumferential surface of the pipe, as seen in a cross-section of the pipe (12). 
Jedno-cijevni kolektor prema zahtjevu 1, naznačen time što su udubljenja i/ili povišenja (16) jednoliko raspoređena oko unutarnje obodne površine cijevi, kao što se vidi na poprečnom presjeku cijevi (12).
The single pipe collector according to claim 1 or 2, characterised in that the direction of the helically extending indentations and/or elevations (16) is altered at least every two meters, in the longitudinal direction (L) of the pipe. 
Jedno-cijevni kolektor prema zahtjevu 1 ili 2, naznačen time što se smjer udubljenja i/ili povišenja (16) koja se pružaju kao heliks (16) mijenja barem svaka dva metra u longitudinalnom smjeru (L) cijevi.
A heat pump system, characterised in that it comprises a single pipe collector according to any of the claims 1-5. 
Sustav toplinske pumpe, naznačen time što obuhvaća jedno-cijevni kolektor prema bilo kojem od zahtjeva 1-5.
Use according to claim 3, wherein the site of administration is a surgical wound. 
Uporaba u skladu s patentnim zahtjevom 3, naznačena time, da je mjesto primjene kirurška rana.
the alloy is cast in a die the temperature of which is controlled in the range of 180-340°C, 
legura je odljevena u kalupu na temperaturi koja se kontrolira u rasponu od 180 do 340°C,
the static metal pressures being maintained during casting between 20-70 MPa and is subsequently intensified up to 180 MPa. 
statički tlak metala se održava prilikom lijevanja između 20 i 70 MPa i naknadno se pojačava do 180 MPa.
The process according to the claim 10, wherein the amount of lanthanum is at least 15 % by weight of the total content of RE-metals, preferably at least 20 % by weight. 
Postupak prema zahtjevu 10, naznačen time, da je količina lantana najmanje 15 masenih % od ukupnog sadržaja RE-metala, poželjno najmanje 20 masenih %.
The process according to anyone of the claims 10-12, wherein the amount of neodymium is at least 7 % by weight of the total content of RE-metals, preferably at least 10 % by weight. 
Postupak prema bilo kojem zahtjevu 10 do 12, naznačen time, da je količina neodimija najmanje 7 masenih % od ukupnog sadržaja RE-metala, poželjno najmanje 10 masenih %.
The process according to anyone of the claims 10-14, wherein the amount of praseodymium is at least 2 % by weight of the total content of R-metals, preferably at least 4 % by weight. 
Postupak prema bilo kojem zahtjevu 10 do 14, naznačen time, da je količina praseodimija najmanje 2 masena % od ukupnog sadržaja RE-metala, poželjno najmanje 4 masena %.
-(C=O)m-NR10R11, wherein R10 and R11 are independently selected from the group consisting of: hydrogen, 
-(C=O)m-NR10R11, gdje su R10 i R11 nezavisno izabrani iz grupe koju čine: vodik,
C1-6alkyl, which is unsubstituted or substituted with R14, 
C1-6alkil, koji je nesupstituiran ili supstituiran sa R14,
C3-6alkenyl, which is unsubstituted or substituted with R14, 
C3-6alkenil, koji je nesupstituiran ili supstituiran sa R14,
C3-6alkynyl, which is unsubstituted or substituted with R14, 
C3-6alkinil, koji je nesupstituiran ili supstituiran sa R14,
C3-6cycloalkyl which is unsubstituted or substituted with R14, 
C3-6cikloalkil koji je nesupstituiran ili supstituiran sa R14,
phenyl, which is unsubstituted or substituted with R14, and 
fenil, koji je nesupstituiran ili supstituiran sa R14, i
heterocycle, which is unsubstituted or substituted with R13, 
heterociklus, koji je nesupstituiran ili supstituiran sa R13,
and R5 are independently selected from hydrogen and C1-6alkyl, which is unsubstituted or substituted with one or more substituents selected from R13, or R4 and R5 may be joined together to form a C3-6cycloalkyl with the carbon atom to which they are attached, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from R13; 
i R5 nezavisno su izabrani od vodika i C1-6alkila, koji je nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13, ili R4 i R5 mogu biti zajedno spojeni tako da formiraju C3-6cikloalkil sa atomom ugljika za koji su vezani, pri čemu je cikloalkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13;
is selected from the group consisting of: halogen, hydroxyl, 
je izabran iz grupe koju čine: halogen, hidroksil,
is selected from the group consisting of: hydroxyl, halogen, 
je izabran iz grupe koju čine: hidroksil, halogen,
The compound of Claim 1 wherein A is phenyl or heteroaryl. 
Spoj prema patentnom zahtjevu 1 gdje je A jednako fenil ili heteroaril.
The compound of Claim 1 wherein R2a, R2b and R2c are independently selected from the group consisting of: hydrogen, halogen, 
Spoj prema patentnom zahtjevu 1 gdje su R2a, R2b i R2c nezavisno izabrani iz grupe koju čine: vodik, halogen,
hydroxyl, C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl, phenyl or naphthyl, 
hidroksil, C1-6alkil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil, fenil ili naftil,
-O-C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, 
-O-C1-6alkil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil ili fenil,
hydroxyl, C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl or naphthyl, 
hidroksil, C1-6alkil, koji je nesupstituiran ili supstituiran sa halogenom, hidroksil ili fenil ili naftil,
-O-C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, 
-O-C1-6alkil, koji je nesupstituiran ili supstituiran sa halogenom, hidroksil ili fenil,
The compound of Claim 9 wherein R2a, R2b and R2c are independently selected from the group consisting of: hydrogen, halogen, 
Spoj prema patentnom zahtjevu 9, naznačen time što su R2a, R2b i R2c nezavisno izabrani iz grupe koju čine: vodik, halogen,
C1-6alkyl, which is unsubstituted or substituted with halogen, 
C1-6alkil, koji je nesupstituiran ili supstituiran sa halogenom,
-O-C1-6alkyl, which is unsubstituted or substituted with halogen, and 
-O-C1-6alkil, koji je nesupstituiran ili supstituiran sa halogenom, i
The compound of Claim 1 wherein R4 is hydrogen or C1-6alkyl and R5 is hydrogen or C1-6alkyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što je R4 jednako vodik ili C1-6alkil i R5 je vodik ili C1-6alkil.
A compound of Claim 1 which is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine:
A compound according to any of claims 1-14 for use in a method for the treatment or prevention of a sleep disorder, or in enhancing the quality of sleep, or in treating or controlling obesity in a mammalian patent in need thereof, optionally in combination with another drug. 
Spoj prema bilo kojem od patentnih zahtjeva 1-14 za upotrebu u postupku za liječenje ili prevenciju poremećaja spavanja, ili u povećanju kvalitete sna, ili u liječenju ili kontroli debljine kod pacijenta-sisavca kod kojeg postoji potreba za tim, izborno u kombinaciji sa drugim lijekom.
R9, at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R9a, and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O and S; 
, svaki put kada je prisutan, je nezavisno izabran između vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, pri čemu alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a, gdje heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;